Vixotrigine
- Generic Name
- Vixotrigine
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19FN2O2
- CAS Number
- 934240-30-9
- Unique Ingredient Identifier
- QQS4J85K6Y
- Background
Vixotrigine has been investigated for the treatment of Bipolar Disorder and Bipolar Depression.
Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Participants With Painful Diabetic Polyneuropathy
- Conditions
- Healthy VolunteersDiabetic Neuropathies
- Interventions
- First Posted Date
- 2019-09-26
- Last Posted Date
- 2021-03-22
- Lead Sponsor
- Biogen
- Registration Number
- NCT04106050
802NP302 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia
- First Posted Date
- 2018-08-20
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Biogen
- Registration Number
- NCT03637387
Study to Evaluate the Effect of UGT Inhibition by Valproic Acid on the Pharmacokinetics of BIIB074
- First Posted Date
- 2017-12-28
- Last Posted Date
- 2018-04-20
- Lead Sponsor
- Biogen
- Target Recruit Count
- 30
- Registration Number
- NCT03385525
- Locations
- 🇺🇸
Research Site, Dallas, Texas, United States
Efficacy and Safety Study of BIIB074 in Participants With Small Fiber Neuropathy
- Conditions
- Small Fiber NeuropathyDiabetes Mellitus
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-11-13
- Last Posted Date
- 2021-05-05
- Lead Sponsor
- Biogen
- Target Recruit Count
- 265
- Registration Number
- NCT03339336
- Locations
- 🇫🇷
CHU Nice - Hôpital de l'Archet 1, Nice, France
🇨🇿Nemocnice Pardubickeho kraje a.s. Pardubicka nemocnice, Pardubice, Czechia
🇩🇪Diabetologische Schwerpunktpraxis Harburg, Hamburg, Germany
A Drug Interaction Study of BIIB074 and an Oral Contraceptive Regimen
- Conditions
- Drug Interactions
- Interventions
- Drug: OC (ethinyl estradiol and levonorgestrel)
- First Posted Date
- 2017-10-30
- Last Posted Date
- 2018-09-25
- Lead Sponsor
- Biogen
- Target Recruit Count
- 36
- Registration Number
- NCT03324685
- Locations
- 🇺🇸
Research Site, Daytona Beach, Florida, United States
802NP301 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Biogen
- Registration Number
- NCT03070132
Extension Study to Evaluate the Long-Term Safety, Tolerability, and Maintenance of Effect of BIIB074
- Conditions
- Neuropathic Pain From Lumbosacral Radiculopathy
- Interventions
- First Posted Date
- 2016-11-08
- Last Posted Date
- 2019-02-25
- Lead Sponsor
- Biogen
- Target Recruit Count
- 302
- Registration Number
- NCT02957617
- Locations
- 🇬🇧
Research Site, London, United Kingdom
🇷🇸Research Site 1, Belgrade, Serbia
🇷🇸Research Site 2, Belgrade, Serbia
Study to Evaluate the Efficacy and Safety of BIIB074 in Neuropathic Pain From Lumbosacral Radiculopathy
- First Posted Date
- 2016-10-17
- Last Posted Date
- 2018-08-15
- Lead Sponsor
- Biogen
- Target Recruit Count
- 502
- Registration Number
- NCT02935608
- Locations
- 🇸🇰
Reasearch Site, Dubnica nad Váhom, Slovakia
🇬🇧Research Site, London, United Kingdom
A Phase 2a Study of BIIB074 in the Treatment of Erythromelalgia
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2018-01-10
- Lead Sponsor
- Biogen
- Target Recruit Count
- 8
- Registration Number
- NCT02917187
- Locations
- 🇺🇸
Research SIte, New London, Connecticut, United States
🇺🇸Research Site, Morgantown, West Virginia, United States
PK and Safety Study of BIIB074 in Healthy Japanese and Caucasian Participants
- First Posted Date
- 2016-07-13
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Biogen
- Target Recruit Count
- 64
- Registration Number
- NCT02831517
- Locations
- 🇬🇧
Research Site, Leeds, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.